RELIEF THERAPEUTICS Holding AG
ISIN: CH0100191136 | Ticker: RLF
Relief is a biopharmaceutical company whose objective is to provide patients with therapeutic RELIEF in serious diseases with high unmet medical need.
We focus on clinical-stage programs based on molecules with a history of clinical use (well-established safety and tolerability) and either initial human activity or efficacy data (proof of concept) or a strong scientific rationale. This allows us to identify molecules where clinical development can be swift (trials with evaluation windows of weeks or months) and cost effective. Our lead compound is RLF-100â„¢, a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action, for respiratory indications. The development program currently is focused on COVID-19-induced severe lung injury and pulmonary sarcoidosis. These are two diseases for which an unmet medical need exists. Clinical development opportunities of RLF-100â„¢ for other indications in both acute and chronic lung diseases are being evaluated.
2013
Served areaWorldwide
HeadquartersAvenue de Sécheron 15, 1202 Genève – Switzerland
4,413,334,617
IPOSept. 19, 2011
Stock exchange(s)SIX Swiss Exchange